The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | EO2463: a vaccine as a monotherapy or in combination with standard chemotherapy in NHL
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses EO2463, a vaccine immunotherapy for indolent non-Hodgkin lymphoma (NHL). EO2463 has shown favorable safety and efficacy as a monotherapy and is now being tested in combination with lenalidomide and/or rituximab. This immunotherapy has the potential to enhance response durability by engaging the immune system to suppress the malignancy long-term. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
